Department of Psychiatry, University of Minnesota, MMC 392, Minneapolis, MN 55455, USA.
Psychopharmacology (Berl). 2010 Oct;212(3):419-29. doi: 10.1007/s00213-010-1968-7. Epub 2010 Aug 6.
Evidence suggests that the progesterone metabolite allopregnanolone (ALLO) decreases cocaine seeking in animal models of relapse.
The purpose of this study was to examine the effects of ALLO on an animal model of cocaine and sucrose bingeing (escalation). Allopregnanolone's effects on yohimbine-induced sucrose intake were also examined. In a separate group of animals, dose interactions between ALLO and cocaine were examined with an abbreviated procedure, a short access progressive ratio (PR) schedule for cocaine reinforcement.
Female rats were treated with ALLO (15 mg/kg, s.c.) or vehicle (VEH) and trained to lever press for cocaine infusions (0.4 mg/kg) under an extended-access procedure. In a separate condition, other ALLO- and VEH-treated female rats self-administered orally delivered liquid sucrose. Allopregnanolone and VEH treatment was then discountinued and the sucrose-maintained rats were administered priming injections of saline, yohimbine, or yohimbine + ALLO. For the PR condition, rats were first treated with VEH until reaching stability at four doses of cocaine (0.2, 0.4, 0.8, and 1.6 mg/kg in mixed order). Subsequently, rats re-established their baseline cocaine intake at the four cocaine doses following treatment with each of two counterbalanced doses of ALLO (15 and 30 mg/kg).
ALLO significantly blocked the escalation of cocaine self-administration but did not reliably affect intake of sucrose under a similar condition or affect cocaine intake at several doses under a PR schedule. Yohimbine significantly increased sucrose intake while ALLO failed to attenuate this increase.
These findings indicate that ALLO protects against binge-like patterns of cocaine intake but does not reduce sugar intake that is acutely increased by yohimbine in females.
有证据表明,孕激素代谢产物别孕烯醇酮(ALLO)可减少动物复吸模型中的可卡因觅药行为。
本研究旨在观察 ALLO 对可卡因和蔗糖 binge (递增)动物模型的影响。还研究了 ALLO 对育亨宾诱导的蔗糖摄入的影响。在另一组动物中,通过缩短可卡因强化的短程渐进比例(PR)程序,检查了 ALLO 与可卡因之间的剂量相互作用。
雌性大鼠接受 ALLO(15mg/kg,皮下)或载体(VEH)治疗,并在延长访问程序下接受可卡因输注(0.4mg/kg)的按压杠杆训练。在另一种情况下,其他接受 ALLO 和 VEH 治疗的雌性大鼠口服给予液体蔗糖。然后停止 ALLO 和 VEH 治疗,并用生理盐水、育亨宾或育亨宾+ALLO 对蔗糖维持大鼠进行启动注射。对于 PR 条件,大鼠首先用 VEH 治疗,直到在四个可卡因剂量(以混合顺序 0.2、0.4、0.8 和 1.6mg/kg)下达到稳定。随后,在接受两种平衡剂量的 ALLO(15 和 30mg/kg)中的每一种治疗后,大鼠在四个可卡因剂量下重新建立基线可卡因摄入量。
ALLO 显著阻断了可卡因自我给药的递增,但在类似条件下,对蔗糖的摄入量没有可靠影响,或在 PR 方案下,对几个可卡因剂量的摄入量没有影响。育亨宾显著增加了蔗糖的摄入量,而 ALLO 未能减轻这种增加。
这些发现表明,ALLO 可防止类似 binge 的可卡因摄入模式,但不能减少女性中急性育亨宾增加的糖摄入量。